Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis - XML Representation

Raw xml | Download



<Group xmlns="http://hl7.org/fhir">
  <id value="179785"/>
  <meta>
    <versionId value="4"/>
    <lastUpdated value="2023-12-04T20:30:06.799Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Group</b><a name="179785"> </a><a name="hc179785"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceGroup &quot;179785&quot; Version &quot;4&quot; Updated &quot;2023-12-04 20:30:06+0000&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparator-definition.html">ComparatorDefinition</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Title</b>: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis</p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/179785">https://fevir.net/resources/Group/179785</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: any-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier/179785</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis</p><p><b>description</b>: Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ATTACC comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ACTIV-4a comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: REMAP-CAP comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785."/>
    </valueRelatedArtifact>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
    <valueString
                 value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
    <valueUri value="https://fevir.net/resources/Group/179785"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
    <valueString value="Computable Publishing LLC"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
    <valueMarkdown
                   value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
    <valueContactDetail>
      <telecom>
        <system value="email"/>
        <value value="support@computablepublishing.com"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
    <valueCode value="any-of"/>
  </extension>
  <modifierExtension
                     url="http://hl7.org/fhir/StructureDefinition/artifact-status">
    <valueCode value="active"/>
  </modifierExtension>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179785"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <type value="animal"/>
  <membership value="definitional"/>
  <name
        value="ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis"/>
  <description
               value="Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial."/>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="ATTACC comparator arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="ACTIV-4a comparator arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="REMAP-CAP comparator arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
</Group>